Compare REGN & SNOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | SNOW |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 87.1B |
| IPO Year | 1995 | 2020 |
| Metric | REGN | SNOW |
|---|---|---|
| Price | $746.39 | $178.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 44 |
| Target Price | ★ $819.54 | $247.30 |
| AVG Volume (30 Days) | 559.3K | ★ 5.7M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 41.48 | N/A |
| Revenue | ★ $5,872,227,000.00 | $3,626,396,000.00 |
| Revenue This Year | $11.69 | $27.93 |
| Revenue Next Year | $10.06 | $23.00 |
| P/E Ratio | $17.98 | ★ N/A |
| Revenue Growth | 20.82 | ★ 29.21 |
| 52 Week Low | $476.49 | $120.10 |
| 52 Week High | $821.11 | $280.67 |
| Indicator | REGN | SNOW |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 49.47 |
| Support Level | $740.39 | $155.35 |
| Resistance Level | $788.69 | $225.26 |
| Average True Range (ATR) | 21.98 | 8.21 |
| MACD | -4.12 | 2.39 |
| Stochastic Oscillator | 6.97 | 79.28 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.